Azafaros Begins Phase 3 Trials for Rare Genetic Diseases
July 28, 2025
First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Azafaros, a company focused on developing treatments for